WebBIOVECTOR THERAPEUTICS SA Overview Total Patents 56 About BIOVECTOR THERAPEUTICS SA has a total of 56 patent applications. Its first patent ever was published in 1989. It filed its patents most often in EPO (European Patent … WebBiovector nanoparticles improve antinociceptive efficacy of nasal morphine These results show the presence of nanoparticles only at a very specific dose increases the antinociceptive activity of nasal morphine in mice. The occurrence of a direct transport of morphine from the nasal mucosa to the brain is discussed.

Patents Assigned to Biovector Therapeutics, S.A. - Justia …

WebNov 4, 1998 · PARIS Biovector Therapeutics¿ nasally administered influenza vaccine has successfully completed a Phase I clinical trial, which entailed the administration of a trivalent vaccine using the company¿s proprietary Biovector Light delivery system. The use of a nasal spray is designed to trigger the production of antibodies at the nasal mucus ... WebMar 24, 1999 · PARIS ¿ The French drug-delivery company Biovector Therapeutics SA has signed separate feasibility agreements with Chiron Corp., of Emeryville, Calif., and Bayer Corp., of Pittsburgh, for the assessment of Biovector¿s proprietary DNA delivery technology platforms in DNA vaccine applications and the expression of blood-circulating … how to take pmp certification

Synthetic biomimetic supra molecular Biovector™ (SMBV™) …

WebJul 5, 1997 · 1 Biovector Therapeutics, Chemin du Chêne vert, Labège, France. PMID: 9247164 DOI: 10.1016/s0005-2736 (97)00041-2 Abstract In this paper a new drug carrier, the Light-biovector, is described. These biovectors are composed of a neutral, anionic or cationic polysaccharidic core surrounded by phospholipids. WebJul 1, 1998 · Biovector Therapeutics is also teaming with BioChem to develop an influenza vaccine nasal spray. These preparations are not only generally more acceptable to children, they also trigger mucosal IgA antibodies. Finally, genetically engineered plants are being developed with antigens that trigger immunity to certain diseases in humans. The early ... WebSep 23, 1998 · Biovector Therapeutics, which is based near Toulouse, in southwestern France, and employs some 60 people, has developed proprietary drug delivery systems called “biovectors“ - synthetic particles that mimic living organisms. It has patented four systems designed to deliver various antigens and genes for the pharmaceutical … how to take po print in sap